NCT02424877

Brief Summary

The purpose of this study is to determine whether automated remote monitoring of patients with early rheumatoid arthritis by the SandRA software and short message service of cell phones increases patient compliance and helps to identify patients needing re-assessment of medication before scheduled visits. This might result in better clinical outcome and cost-effectiveness.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
165

participants targeted

Target at P75+ for not_applicable rheumatoid-arthritis

Timeline
Completed

Started Aug 2013

Typical duration for not_applicable rheumatoid-arthritis

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2013

Completed
1.7 years until next milestone

First Submitted

Initial submission to the registry

April 20, 2015

Completed
3 days until next milestone

First Posted

Study publicly available on registry

April 23, 2015

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 30, 2016

Completed
11 months until next milestone

Study Completion

Last participant's last visit for all outcomes

January 2, 2017

Completed
Last Updated

October 5, 2017

Status Verified

October 1, 2017

Enrollment Period

2.5 years

First QC Date

April 20, 2015

Last Update Submit

October 4, 2017

Conditions

Keywords

rheumatoid arthritisdrug treatmentcomplianceoutcome

Outcome Measures

Primary Outcomes (1)

  • remission

    number of remissions at each arm, defined by no tender or swollen joints (44 joints) and normal CRP

    at 6 months (co-primary 12 months)

Secondary Outcomes (4)

  • patient confidence

    at 0, 3, and 6 months

  • quality of life

    at 0, 3, and 6 months

  • drug adherence

    during 6 months

  • consumption of resources

    during 6 months

Study Arms (2)

SandRA

EXPERIMENTAL

cell phone monitoring

Procedure: SandRA

Control

NO INTERVENTION

conventional monitoring

Interventions

SandRAPROCEDURE

SandRA software sends SMS messages to a patient asking questions about the usage and adverse effects of prescribed drugs and about the severity of rheumatoid arthritis. The answer messages are interpreted automatically.

SandRA

Eligibility Criteria

Age17 Years+
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Fulfillment of the EULAR 2010 classification criteria for rheumatoid arthritis
  • Commencement of the first anti rheumatic medication
  • Ability to use short message service of cell phones,
  • Comprehension of the function of the SandRA monitoring system
  • Willingness to participate.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Central Finland Central Hospital

Jyväskylä, FI-40620, Finland

Location

South Karelia Central Hospital

Lappeenranta, FI-53130, Finland

Location

Related Publications (7)

  • Mottonen T, Hannonen P, Leirisalo-Repo M, Nissila M, Kautiainen H, Korpela M, Laasonen L, Julkunen H, Luukkainen R, Vuori K, Paimela L, Blafield H, Hakala M, Ilva K, Yli-Kerttula U, Puolakka K, Jarvinen P, Hakola M, Piirainen H, Ahonen J, Palvimaki I, Forsberg S, Koota K, Friman C. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet. 1999 May 8;353(9164):1568-73. doi: 10.1016/s0140-6736(98)08513-4.

    PMID: 10334255BACKGROUND
  • Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, Kincaid W, Porter D. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet. 2004 Jul 17-23;364(9430):263-9. doi: 10.1016/S0140-6736(04)16676-2.

    PMID: 15262104BACKGROUND
  • Brus H, van de Laar M, Taal E, Rasker J, Wiegman O. Determinants of compliance with medication in patients with rheumatoid arthritis: the importance of self-efficacy expectations. Patient Educ Couns. 1999 Jan;36(1):57-64. doi: 10.1016/s0738-3991(98)00087-1.

    PMID: 10036560BACKGROUND
  • Schoels M, Kapral T, Stamm T, Smolen JS, Aletaha D. Step-up combination versus switching of non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a retrospective observational study. Ann Rheum Dis. 2007 Aug;66(8):1059-65. doi: 10.1136/ard.2006.061820. Epub 2007 Feb 16.

    PMID: 17307765BACKGROUND
  • Rohekar G, Pope J. Test-retest reliability of patient global assessment and physician global assessment in rheumatoid arthritis. J Rheumatol. 2009 Oct;36(10):2178-82. doi: 10.3899/jrheum.090084. Epub 2009 Sep 15.

    PMID: 19755617BACKGROUND
  • Pincus T, Bergman M, Sokka T, Roth J, Swearingen C, Yazici Y. Visual analog scales in formats other than a 10 centimeter horizontal line to assess pain and other clinical data. J Rheumatol. 2008 Aug;35(8):1550-8. Epub 2008 Jun 15.

    PMID: 18597409BACKGROUND
  • Kuusalo L, Sokka-Isler T, Kautiainen H, Ekman P, Kauppi MJ, Pirila L, Rannio T, Uutela T, Yli-Kerttula T, Puolakka K; SandRA Study Group. Automated Text Message-Enhanced Monitoring Versus Routine Monitoring in Early Rheumatoid Arthritis: A Randomized Trial. Arthritis Care Res (Hoboken). 2020 Mar;72(3):319-325. doi: 10.1002/acr.23846.

MeSH Terms

Conditions

Arthritis, RheumatoidPatient Compliance

Condition Hierarchy (Ancestors)

ArthritisJoint DiseasesMusculoskeletal DiseasesRheumatic DiseasesConnective Tissue DiseasesSkin and Connective Tissue DiseasesAutoimmune DiseasesImmune System DiseasesPatient Acceptance of Health CareTreatment Adherence and ComplianceHealth BehaviorBehavior

Study Officials

  • Kari Puolakka, MD, PhD

    South Carelia Central Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 20, 2015

First Posted

April 23, 2015

Study Start

August 1, 2013

Primary Completion

January 30, 2016

Study Completion

January 2, 2017

Last Updated

October 5, 2017

Record last verified: 2017-10

Data Sharing

IPD Sharing
Will not share

Locations